BioSpace News Archive

Cubic Corporation announced that it has entered a partnership agreement with the University of Alabama in Huntsville College of Nursing to use the Learning and Technology Resource Center’s Human Patient Simulator iStan to test an emergency ventilator device the company is developing in anticipation of ventilator shortages arising from the COVID-19 pandemic.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application submitted by its collaborator, Novartis, for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease (SCD). This Pha

Encompass Health Corp. announced it will report results for its first quarter ending March 31, 2020, after the market closes on April 28, 2020.

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19

Kleo Pharmaceuticals Inc announced today that it has entered into a research collaboration with South Korea -based Green Cross LabCell (GCLC),

Animal studies show a complete and statistically significant (p <0.0001) inhibition of tumor growth

Resverlogix Corp. announced its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology, presenting two virtual posters made available on demand via an eAbstracts System starting Saturday, March 28, 2020.

Windtree Therapeutics, Inc. announces it has entered into a binding term sheet (the “Term Sheet”) with Lee’s Pharmaceutical Holdings (HK) Ltd

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, announced that Arthur DeCillis, MD, has joined the company as Acting CMO.

Axovant Gene Therapies Ltd., a clinical-stage company developing innovative gene therapies for neurological diseases, announced that management will participate in the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day on Friday, April 3, 2020.